Search global stocks & ETFs...Ctrl K

Learn Mode

NTLA - Intellia Therapeutics Inc

74

$13.67

$0.58 (4.431%)

At market close

$13.52

-$0.15 (-1.130%)

After Hours 5/15/26, 11:38 PM

Score

2.29/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

NTLA

Valuation Score

View as %

Stock Unlock

YTD

Max

Stock Profile

Market Cap

$1.91B

Industry

Biotechnology

EPS (TTM)

-$3.55

P/E (TTM)

0.00

Div & Yield

FCF Payout Ratio

P/S (TTM)

28.22

P/B

2.84

Diluted Shares

115.98M

Ex-Dividend

Next Earnings

08-05

Forward P/E

0.00

Payout Ratio

P/FCF (TTM)

0.00

FCF Yield

Earnings Yield

-21.61%

52 Week Range

Score Card

Explore Scores Tab

2.29

Bad

Intellia Therapeutics Inc has negative free cash flow of -395.87M, which means it is currently losing money. Also, it has a current cash runway of 13.64 months. The cash runway is the amount of time the business has at its current burn rate before it will need to take on debt or dilute shareholders to raise more money.

Valuation Model

Key Score

5.00

Very Good

Management

5.00

Very Good

Growth

5.00

Very Good

Profitability

1.00

Very Bad

Fin. Health

3.00

Average

Dividends

Analyst

2.00

Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

2 new filings were in the last 7 days

Filter Form Types

Form 10-Q

General form for quarterly financial reports under Section 13 or 15(d)

Filed on 2026-05-11 07:49:18

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-05-11 07:36:17

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-04-30 16:30:29

Form ARS

Unknown Form Type

Filed on 2026-04-30 16:23:19

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-04-30 16:16:55

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-04-30 16:10:38

Form SCHEDULE 13G

Unknown Form Type

Filed on 2026-04-30 10:23:47

Form 424B5

Unknown Form Type

Filed on 2026-04-29 17:28:35

Form SCHEDULE 13G

Unknown Form Type

Filed on 2026-04-29 13:48:49

Form 424B5

Unknown Form Type

Filed on 2026-04-27 17:19:08

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-04-27 09:13:36

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-04-10 16:16:24

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-25

High:

$111.30

714.2%

Avg:

$26.01

90.3%

Low:

$5.05

-63.1%

(% change is relative to the current stock price: $13.67)

Analyst Recommendations

Go to Analyst Tab

3.70

Good

20%

Strong Buy (6)

37%

Buy (11)

37%

Hold (11)

Sell (2)

Strong Sell (0)

About

Website
https://www.intelliatx.com/
Address
40 Erie St Ste 130, Cambridge MASSACHUSETTS, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1652130

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. The company is headquartered in Cambridge, Massachusetts and currently employs 377 full-time employees. The company went IPO on 2016-05-06. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The firm is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. The company is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.

IPO Date

2016-05-06

Industry

Biotechnology

Total Employees

377

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences

NTLA - Intellia Therapeutics Inc

74

$13.67

$0.58 (4.431%)

$13.52

-$0.15 (-1.130%)

2.29/5

Stock Unlock

Stock Profile

Score Card

Bad

Insider Transactions

Market News

Form 10-Q

Filed on 2026-05-11 07:49:18

Form 8-K

Filed on 2026-05-11 07:36:17

Form 8-K

Filed on 2026-04-30 16:30:29

Form ARS

Filed on 2026-04-30 16:23:19

Form DEFA14A

Filed on 2026-04-30 16:16:55

Form DEF 14A

Filed on 2026-04-30 16:10:38

Form SCHEDULE 13G

Filed on 2026-04-30 10:23:47

Form 424B5

Filed on 2026-04-29 17:28:35

Form SCHEDULE 13G

Filed on 2026-04-29 13:48:49

Form 424B5

Filed on 2026-04-27 17:19:08

Form 8-K

Filed on 2026-04-27 09:13:36

Form 8-K

Filed on 2026-04-10 16:16:24

Financials

Price Targets

714.2%

90.3%

-63.1%

Analyst Recommendations

About

Similar Stocks